Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Lentz, John
NCT05706506: A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)	Completed	4	152	US	Tirzepatide, LY3298176	Eli Lilly and Company	Type 2 Diabetes, Diabetes Mellitus, Type 2	10/23	10/23
NCT05968430: Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects with Hypertension	Enrolling by invitation	3	1400	Europe, Canada, US, RoW	lorundrostat, Placebo	Mineralys Therapeutics Inc.	Hypertension	12/25	12/26
NCT05769608: A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen	Completed	2	285	US	Placebo, lorundrostat Dose 1, lorundrostat Dose 2	Mineralys Therapeutics Inc.	Hypertension	01/25	01/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Lentz, John
NCT05706506: A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)	Completed	4	152	US	Tirzepatide, LY3298176	Eli Lilly and Company	Type 2 Diabetes, Diabetes Mellitus, Type 2	10/23	10/23
NCT05968430: Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects with Hypertension	Enrolling by invitation	3	1400	Europe, Canada, US, RoW	lorundrostat, Placebo	Mineralys Therapeutics Inc.	Hypertension	12/25	12/26
NCT05769608: A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen	Completed	2	285	US	Placebo, lorundrostat Dose 1, lorundrostat Dose 2	Mineralys Therapeutics Inc.	Hypertension	01/25	01/25